Cosmos Health CEO acquires $44,999 in stock through debt exchange

Published 05/03/2025, 17:08
Cosmos Health CEO acquires $44,999 in stock through debt exchange

Cosmos Health Inc. (NASDAQ:COSM), a company currently valued at $11 million market cap and rated ’FAIR’ on InvestingPro’s Financial Health Score, saw its CEO Grigorios Siokas acquire 85,714 shares of the company’s common stock, according to a recent SEC filing. The shares were acquired at a price of $0.525 each, totaling approximately $44,999. This transaction was part of a debt exchange agreement, where Siokas received the shares in exchange for a $45,000 debt owed to him by the company. Following this acquisition, Siokas now holds a total of 4,115,302 shares in Cosmos Health. The stock, which InvestingPro analysis indicates is currently undervalued, has experienced significant volatility, declining over 50% in the past six months. Discover more insights and 10 additional ProTips for COSM on InvestingPro.

In other recent news, Cosmos Health Inc. has postponed its planned securities offering as it prepares to file its Annual Report for the fiscal year ending December 31, 2024. The company has not specified a new date for the offering, indicating it will proceed after the report is filed. Additionally, Cosmos Health is advancing its weight management product, CCX0722, toward clinical trials, with a market launch anticipated in the first half of 2026. The company is actively engaging with Contract Research Organizations to complete the necessary technical dossier for regulatory submission. In another development, Cosmos Health has filed new patent applications for treatments targeting glioma and hematologic malignancies, expanding its intellectual property portfolio. This move highlights the company’s collaboration with Cloudpharm and the National Hellenic Research Foundation. Furthermore, Cosmos Health has secured a 10-year contract manufacturing agreement with Provident Pharmaceuticals through its subsidiary, Cana Laboratories. This agreement involves the production of 800,000 packs of pharmaceutical products annually. Lastly, Cosmos Health has filed a patent application for a new allergy inflammation treatment, supported by its AI-powered Cloudscreen drug repurposing platform.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.